Rettiganti, Mallikarjuna
Eli Lilly (United States)
3 papers on CoChat
Most cited papers
- Verified
A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
Knop, F. K., Urva, S., Rettiganti, M., Benson, C. T., Roell, W. C., Mather, K. J., Haupt, A., & Pratt, E. J. (2024) · Diabetes, Obesity and Metabolism
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 41
- Verified
56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting
KNOP, F. K., URVA, S., RETTIGANTI, M., BENSON, C., ROELL, W., MATHER, K. J., HAUPT, A., & PRATT, E. J. (2023) · Diabetes
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 29
- Verified
Mouse and cockroach exposure in rural Arkansas Delta region homes
Coleman, A. T., Rettiganti, M., Bai, S., Brown, R. H., & Perry, T. T. (2014) · Annals of Allergy, Asthma & Immunology
Indoor Air Quality and Microbial ExposureAllergic Rhinitis and Sensitization
Cited by 10
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free